Genethera Stock Book Value Per Share
| GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera fundamentals help investors to digest information that contributes to GeneThera's financial success or failures. It also enables traders to predict the movement of GeneThera Pink Sheet. The fundamental analysis module provides a way to measure GeneThera's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneThera pink sheet.
GeneThera |
GeneThera Company Book Value Per Share Analysis
GeneThera's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current GeneThera Book Value Per Share | (0.24) X |
Most of GeneThera's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneThera is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of GeneThera is about -0.242 times. This is 85.76% lower than that of the Healthcare sector and 99.9% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 100.01% higher than that of the company.
GeneThera Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneThera's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of GeneThera could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics of similar companies.GeneThera is currently under evaluation in book value per share category among its peers.
GeneThera Fundamentals
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Shares Owned By Insiders | 17.99 % | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Net Income | (1.01 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (8.57 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | 0.89 | |||
| Market Capitalization | 533.53 K | |||
| Total Asset | 6.3 K | |||
| Retained Earnings | (25.59 M) | |||
| Working Capital | (7.03 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 7.08 M | |||
| Net Asset | 6.3 K |
About GeneThera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneThera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneThera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneThera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.